Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#71 / 200 Total
OCUL - Ocular Therapeutix Inc - Stock Price Chart
TickerOCUL [NASD, RUT]
CompanyOcular Therapeutix Inc
CountryUSA
IndustryBiotechnology
Market Cap1.17BEPS (ttm)-1.26
P/E-EPS this Y0.74%
Forward P/E-EPS next Y-6.24%
PEG-EPS past 5Y8.51%
P/S18.32EPS next 5Y4.84%
P/B3.67EPS Q/Q16.79%
Dividend-Sales Q/Q15.40%
Insider Own15.79%Inst Own72.49%
Insider Trans-0.30%Inst Trans-5.74%
Short Float9.58%EarningsMar 03/b
Analyst Recom1.08Target Price17.58
Avg Volume1.27M52W Range4.06 - 11.77
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dugel PravinSee RemarksFeb 24 '25Sale6.8721,475147,5333,520,318Feb 26 06:27 PM
Heier Jeffrey S.Chief Scientific OfficerFeb 24 '25Sale6.873,06121,029265,998Feb 26 06:25 PM
Kaiser PeterChief Development OfficerFeb 24 '25Sale6.873,00920,672210,078Feb 26 06:24 PM
Nayak SanjayChief Strategy OfficerFeb 24 '25Sale6.841,89512,962283,485Feb 26 06:22 PM
PETER KAZUO KAISEROfficerFeb 24 '25Proposed Sale6.873,00920,684Feb 24 04:54 PM
BKTI - BK Technologies Corp - Stock Price Chart
TickerBKTI [AMEX]
CompanyBK Technologies Corp
CountryUSA
IndustryCommunication Equipment
Market Cap158.14MEPS (ttm)2.22
P/E19.98EPS this Y21.74%
Forward P/E14.37EPS next Y10.00%
PEG-EPS past 5Y-
P/S2.06EPS next 5Y-
P/B5.30EPS Q/Q1019.90%
Dividend-Sales Q/Q9.93%
Insider Own25.68%Inst Own37.79%
Insider Trans-0.17%Inst Trans27.36%
Short Float0.22%EarningsMar 27/b
Analyst Recom1.00Target Price40.00
Avg Volume28.15K52W Range11.67 - 43.34
BK Technologies Corp. is a holding company, which engages in the provision of two-way radio communications equipment. It offers product to the fire, EMS, police, federal, and municipalities agencies. The company was founded on October 24, 1997 and is headquartered in West Melbourne, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Malmanger Scott A.CFO and SecretaryNov 20 '24Option Exercise15.531,00015,5308,302Mar 31 04:17 PM
Lanktree Charles TDirectorDec 04 '24Sale35.0099234,720549Dec 16 05:52 PM
Lanktree Charles TDirectorDec 13 '24Sale36.3154919,9340Dec 16 05:52 PM
Horowitz JoshuaDirectorAug 19 '24Buy19.863,33066,12690,000Aug 19 07:02 PM
Horowitz JoshuaDirectorAug 15 '24Buy16.821,70428,66586,670Aug 19 07:02 PM
NEPH - Nephros Inc - Stock Price Chart
TickerNEPH [NASD]
CompanyNephros Inc
CountryUSA
IndustryMedical Instruments & Supplies
Market Cap21.52MEPS (ttm)0.01
P/E298.53EPS this Y100.00%
Forward P/E50.75EPS next Y100.00%
PEG-EPS past 5Y-
P/S1.52EPS next 5Y-
P/B2.49EPS Q/Q153.39%
Dividend-Sales Q/Q18.93%
Insider Own12.87%Inst Own44.45%
Insider Trans0.00%Inst Trans10.26%
Short Float0.21%EarningsMar 06/a
Analyst Recom1.00Target Price4.75
Avg Volume13.98K52W Range1.36 - 2.55
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Amron Arthur HDirectorMay 30 '24Buy2.243,0006,735103,463May 30 04:35 PM
Amron Arthur HDirectorMay 28 '24Buy2.222,0004,441100,463May 30 04:35 PM
Banks Robert R. Jr.President and CEOMay 16 '24Buy2.2450,000112,05070,000May 16 04:49 PM
RGLS - Regulus Therapeutics Inc - Stock Price Chart
TickerRGLS [NASD, RUT]
CompanyRegulus Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap129.84MEPS (ttm)-0.88
P/E-EPS this Y-42.89%
Forward P/E-EPS next Y-18.35%
PEG-EPS past 5Y40.21%
P/S-EPS next 5Y-3.70%
P/B1.68EPS Q/Q51.00%
Dividend-Sales Q/Q-
Insider Own19.71%Inst Own63.67%
Insider Trans-1.33%Inst Trans-7.80%
Short Float3.83%EarningsMar 13/a
Analyst Recom1.00Target Price10.83
Avg Volume1.11M52W Range0.83 - 2.90
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hagan Joseph PChief Executive OfficerJan 30 '25Buy1.0950,00054,260260,808Jan 31 05:00 PM
BALTIMORE DAVIDDirectorJan 30 '25Buy1.0619,61020,78722,169Jan 31 05:00 PM
Aker Christopher RaySr. VP & General CounselJan 13 '25Sale1.2638,54748,69354,634Jan 15 05:00 PM
Aker Christopher RaySr. VP & General CounselJan 14 '25Sale1.265,0886,42749,546Jan 15 05:00 PM
Hagan Joseph PChief Executive OfficerJan 13 '25Sale1.26115,290145,634222,572Jan 15 05:00 PM
YOSH - Yoshiharu Global Co - Stock Price Chart
TickerYOSH [NASD]
CompanyYoshiharu Global Co
CountryUSA
IndustryRestaurants
Market Cap23.49MEPS (ttm)-2.00
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-82.63%
P/S1.83EPS next 5Y-
P/B90.08EPS Q/Q5803.08%
Dividend-Sales Q/Q47.44%
Insider Own50.94%Inst Own0.52%
Insider Trans0.00%Inst Trans263.78%
Short Float5.26%Earnings-
Analyst Recom-Target Price-
Avg Volume120.66K52W Range2.70 - 22.50
Yoshiharu Global Co. engages in the operation of a Japanese restaurant under the name Yoshiharu Ramen. It offers Japanese ramens, rice bowls, and appetizers. The company was founded by James Chae in 2016 and is headquartered in Buena Park, CA.
DNLI - Denali Therapeutics Inc - Stock Price Chart
TickerDNLI [NASD, RUT]
CompanyDenali Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap2.00BEPS (ttm)-2.58
P/E-EPS this Y-12.76%
Forward P/E-EPS next Y10.84%
PEG-EPS past 5Y-4.46%
P/S-EPS next 5Y7.03%
P/B1.59EPS Q/Q21.93%
Dividend-Sales Q/Q-
Insider Own13.43%Inst Own88.02%
Insider Trans-1.13%Inst Trans0.58%
Short Float8.36%EarningsFeb 27/a
Analyst Recom1.16Target Price36.62
Avg Volume1.15M52W Range12.05 - 33.33
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ho CaroleChief Medical OfficerJan 06 '25Sale20.2212,255247,796178,580Jan 08 08:26 PM
Ho CaroleChief Medical OfficerJan 07 '25Sale20.812,90760,495175,673Jan 08 08:26 PM
Schuth Alexander O.COFO and SecretaryJan 06 '25Sale20.2212,255247,796247,215Jan 08 08:25 PM
Schuth Alexander O.COFO and SecretaryJan 07 '25Sale20.812,90760,495244,308Jan 08 08:25 PM
Watts Ryan J.President and CEOJan 06 '25Sale20.2229,266591,759260,721Jan 08 08:24 PM
AUUD - Auddia Inc - Stock Price Chart
TickerAUUD [NASD]
CompanyAuddia Inc
CountryUSA
IndustrySoftware - Application
Market Cap2.19MEPS (ttm)-62.45
P/E-EPS this Y83.05%
Forward P/E-EPS next Y37.50%
PEG-EPS past 5Y21.77%
P/S-EPS next 5Y-
P/B0.37EPS Q/Q87.39%
Dividend-Sales Q/Q-
Insider Own2.97%Inst Own20.38%
Insider Trans0.00%Inst Trans15.29%
Short Float44.48%EarningsFeb 26
Analyst Recom1.00Target Price425.00
Avg Volume114.27K52W Range3.35 - 96.90
Auddia, Inc. engages in the development of audio content ecosystem technology and products. The firm operates an interactive radio platform called Auddia, which is a subscription based commercial free AM and FM software application. It also offers Vodacast, an interactive podcasting platform and application, which enables listeners to see video and other digital content in a digital feed that correlates with the podcast audio. The company was founded by Jeffrey J. Thramann in 2011 and is headquartered in Boulder, CO.
WLDS - Wearable Devices Ltd - Stock Price Chart
TickerWLDS [NASD]
CompanyWearable Devices Ltd
CountryIsrael
IndustryConsumer Electronics
Market Cap2.20MEPS (ttm)-21.70
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-28.08%
P/S4.22EPS next 5Y-
P/B0.39EPS Q/Q-2185.63%
Dividend-Sales Q/Q82.86%
Insider Own6.26%Inst Own4.52%
Insider Trans0.00%Inst Trans-
Short Float1.11%Earnings-
Analyst Recom-Target Price-
Avg Volume84.06K52W Range1.65 - 54.40
Wearable Devices Ltd. engages in the development of a non-invasive neural input technology that allows operation and control of digital devices using subtle finger movements and fingertip pressure. It offers Mudra band, a neutral input wristband. The company was founded by Asher Dahan, Guy Wagner, and Leeor Langer in March 2014 and is headquartered in Yokne'am Illit, Israel.
ACON - Aclarion Inc - Stock Price Chart
TickerACON [NASD]
CompanyAclarion Inc
CountryUSA
IndustryHealth Information Services
Market Cap7.34MEPS (ttm)-20536.40
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y4.93%
P/S146.73EPS next 5Y-
P/B0.01EPS Q/Q92.20%
Dividend-Sales Q/Q-24.43%
Insider Own0.00%Inst Own0.01%
Insider Trans-Inst Trans-
Short Float0.78%EarningsFeb 26
Analyst Recom3.00Target Price9045.00
Avg Volume205.01K52W Range9.75 - 6241.05
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.
PEPG - PepGen Inc - Stock Price Chart
TickerPEPG [NASD, RUT]
CompanyPepGen Inc
CountryUSA
IndustryBiotechnology
Market Cap47.73MEPS (ttm)-2.84
P/E-EPS this Y6.44%
Forward P/E-EPS next Y9.39%
PEG-EPS past 5Y-116.35%
P/S-EPS next 5Y11.88%
P/B0.40EPS Q/Q16.65%
Dividend-Sales Q/Q-
Insider Own16.57%Inst Own85.67%
Insider Trans-0.05%Inst Trans29.29%
Short Float10.48%EarningsFeb 24/b
Analyst Recom1.60Target Price12.20
Avg Volume2.87M52W Range1.16 - 19.30
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DeLena Mary BethGeneral CounselFeb 26 '25Sale1.681,4322,4061,568Feb 26 08:24 PM
Donnelly NoelChief Financial OfficerFeb 26 '25Sale1.681,5272,5651,673Feb 26 08:12 PM
Mellion Michelle LChief Medical OfficerJul 25 '24Option Exercise10.217,57177,3007,571Jul 26 04:52 PM
Mellion Michelle LChief Medical OfficerJul 24 '24Option Exercise10.212012,052201Jul 26 04:52 PM
Mellion Michelle LChief Medical OfficerJul 25 '24Sale18.067,571136,7410Jul 26 04:52 PM
134567891011121320